Novo Nordisk A/S
Bagsvaerd, Denmark, July 15, 2024 – Novo Nordisk launched a share buyback program on May 6, 2024 in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbor Regulation”). The program is part of an overall share buyback program of up to DKK 20 billion to be carried out over the 12 months from February 6, 2024.
Under the program, which began on May 6, 2024, Novo Nordisk plans to repurchase up to DKK 2.2 billion of B shares between May 7, 2024 and August 5, 2024.
Since the July 8, 2024 announcement, the following transactions have taken place:
number
B stock
average
Purchase price
transaction
Value, Danish Krone
Cumulative, final announcement
1,512,345
1,442,717,161
July 8, 2024
36,500
981.24
35,815,365
July 9, 2024
37,010
970.38
35,913,631
July 10, 2024
36,965
964.30
35,645,476
July 11, 2024
38,000
973.20
36,981,654
July 12, 2024
37,000
972.79
35,993,373
Accumulated based on the program
1,697,820
1,623,066,660
Details of each transaction made under the share repurchase program are available at novonordisk.com.
As a result of the above transactions, Novo Nordisk will hold a total of 11,797,860 B shares (DKK 0.10 each) in treasury shares, representing 0.3% of its share capital. The company’s total A and B shares, including treasury shares, will amount to 4,465,000,000.
Novo Nordisk plans to repurchase up to DKK 20 billion of B shares over a 12-month period beginning on February 6, 2024. As of July 12, 2024, Novo Nordisk has repurchased a total of 10,432,070 B shares at an average price of DKK 877.18 per share since February 6, 2024, representing a transaction value of DKK 9,150,801,432.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Building on our diabetes heritage, our purpose is to drive transformation to overcome serious chronic diseases. We do this by pioneering scientific breakthroughs, expanding access to medicines and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 66,000 people in 80 countries and sells products in approximately 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Novo Nordisk’s ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Please contact us for more details.
Company Notification No. 53/2024
The story continues
Attachments